Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7298728 | 1.00 | MAOB (0.42) | MAOBGAA | |
| SCHEMBL320161 | 0.83 | MAOB (0.45) | MAOBGAA | |
| SCHEMBL3505304 | 0.82 | GPR55 (0.33) | MAOBGAA | |
| SCHEMBL3505299 | 0.82 | GPR55 (0.33) | MAOBGAA | |
| SCHEMBL7300033 | 0.78 | MAOB (0.43) | MAOBGAA | |
| SCHEMBL3506406 | 0.78 | MAOB (0.43) | MAOBGAA | |
| SCHEMBL7302420 | 0.76 | GAA (0.46) | MAOBGAA | |
| SCHEMBL5821188 | 0.74 | HRH3 (0.32) | — | |
| SCHEMBL9424210 | 0.74 | MAOB (0.57) | MAOB | |
| SCHEMBL3504313 | 0.71 | MAOB (0.44) | MAOBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-04-05 | — | — | US | claimed |
| EP-0655445-B1 | 1,3,4-oxadiazol-2(3H)-one Derivates, their preparation and their use as monoamine oxidase inhibitors | SYNTHELABO (FR) | 1997-08-27 | — | — | EP | claimed |
| US-5525619-A | INHIBITORS OF MONOAMINE OXIDASE B | SYNTHELABO (FR) | 1996-06-11 | — | — | US | claimed |
| EP-0655445-A1 | 1,3,4-oxadiazol-2(3H)-one Derivates, their preparation and their use as monoamine oxidase inhibitors | SYNTHELABO (FR) | 1995-05-31 | — | — | EP | claimed |
| US-20100247543-A1 | TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES | ORYZON GENOMICS, S.A. (ES) | 2010-09-30 | — | — | US | disclosed |
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-04-05 | — | — | US | disclosed |
| WO-2006138475-A2 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | MAOB, MAOA, GPR119 | MAOB 1/4885GAA 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.